Component: (Network and Table)
Network
00500 - Statement - Consolidated Statements of Cash Flows
(http://www.veeco.com/role/StatementConsolidatedStatementsOfCashFlows)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Reporting Entity [Axis]0000103145 (http://www.sec.gov/CIK)
Consolidated Statements of Cash FlowsPeriod [Axis]
2016-01-01 - 2016-12-31
2015-01-01 - 2015-12-31
2014-01-01 - 2014-12-31
Consolidated Statements of Cash Flows
 
 
 
Cash Flows from Operating Activities
 
 
 
Net income (loss)
(122,210,000) 
(31,978,000) 
(66,940,000) 
Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities:
 
 
 
Depreciation and amortization
32,650,000  
39,850,000  
24,573,000  
Deferred income taxes
940,000  
2,648,000  
(11,330,000) 
Share-based compensation expense
15,741,000  
17,986,000  
18,813,000  
Asset impairment
69,520,000  
126,000  
58,170,000  
Gain on sale of lab tools
 
(1,261,000) 
(1,549,000) 
Provision (recovery) for bad debts
171,000  
43,000  
(1,814,000) 
Gain on cumulative translation adjustment
(430,000) 
 
(3,142,000) 
Changes in contingent consideration
  
(29,368,000) 
Changes in operating assets and liabilities:
 
 
 
Accounts receivable
(8,667,000) 
10,715,000  
(25,390,000) 
Inventories and deferred cost of sales
(5,389,000) 
(12,312,000) 
6,513,000  
Prepaid expenses and other current assets
6,726,000  
(39,000) 
(2,245,000) 
Accounts payable and accrued expenses
(24,202,000) 
9,470,000  
(5,534,000) 
Customer deposits and deferred revenue
8,807,000  
(20,738,000) 
55,536,000  
Income taxes receivable and payable, net
547,000  
759,000  
20,279,000  
Other, net
1,952,000  
520,000  
5,497,000  
Net cash provided by (used in) operating activities
(23,844,000) 
 
15,789,000  
 
42,069,000  
 
Cash Flows from Investing Activities
 
 
 
Acquisitions of businesses, net of cash acquired
 
(68,000) 
(144,069,000) 
Capital expenditures
(11,479,000) 
(13,887,000) 
(15,588,000) 
Proceeds from the sale of investments
152,301,000  
88,647,000  
318,276,000  
Payments for purchases of investments
(103,394,000) 
(84,244,000) 
(157,737,000) 
Payments for purchase of cost method investment
 
(1,594,000) 
(2,388,000) 
Proceeds from sale of property, plant, and equipment
9,512,000  
  
Proceeds from sale of lab tools
 
3,068,000  
9,259,000  
Other
(230,000) 
1,000,000  
350,000  
Net cash provided by (used in) investing activities
46,710,000  
 
(7,078,000) 
 
8,103,000  
 
Cash Flows from Financing Activities
 
 
 
Proceeds from stock option exercises and employee stock purchase plan
1,656,000  
2,233,000  
12,056,000  
Restricted stock tax withholdings
(2,601,000) 
(3,215,000) 
(2,075,000) 
Purchases of common stock
(13,349,000) 
(8,907,000) 
 
Repayments of long-term debt
(340,000) 
(314,000) 
(290,000) 
Net cash provided by (used) in financing activities
(14,634,000) 
 
(10,203,000) 
 
9,691,000  
 
Effect of exchange rate changes on cash and cash equivalents
(20,000) 
(87,000) 
149,000  
Net increase in cash and cash equivalents
8,212,000  
 
(1,579,000) 
 
60,012,000  
 
Cash and cash equivalents - beginning of period
269,232,000  
270,811,000  
210,799,000  
Cash and cash equivalents - end of period
277,444,000  
 
269,232,000  
 
270,811,000  
 
Supplemental Disclosure of Cash Flow Information
 
 
 
Interest paid
225,000  
485,000  
159,000  
Income taxes paid
1,699,000  
7,091,000  
3,320,000  
Non-cash operating and financing activities
 
 
 
Net transfer of inventory to property, plant and equipment
1,827,000